Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company
Does the March share price for Codexis, Inc. (NASDAQ:CDXS) reflect what it's really worth? Today, we will estimate the...
Charles Schwab Investment Management Inc. increased its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with th
Q4 2019 Codexis Inc Earnings Call
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Stocks That Hit 52-Week Lows On Thursday

04:10pm, Thursday, 12'th Mar 2020
Codexis (NASDAQ:CDXS) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, BidAskClub

Stocks That Hit 52-Week Lows On Wednesday

03:41pm, Wednesday, 11'th Mar 2020
During Wednesday's morning session, 690 stocks hit new 52-week lows. Intriguing Points: Boeing (NYSE: BA) was the biggest company on a market cap basis to set a new...
Appili Therapeutics (APLI CN) initiated with Buy rating and C$4 (602% upside) price target at Maxim Group.Aphria (NYSE:APHA) initiated with Hold rating and C$4.50 (7% upside) price target at Stifel. S
Barclays PLC lifted its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 272.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commiss
Fmr LLC trimmed its position in Codexis, Inc. (NASDAQ:CDXS) by 12.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The f

ValuEngine Downgrades Codexis (NASDAQ:CDXS) to Buy

08:08am, Wednesday, 04'th Mar 2020
Codexis (NASDAQ:CDXS) was downgraded by research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday, ValuEngine reports. A number of o
Analysts expect Codexis, Inc. (NASDAQ:CDXS) to report ($0.03) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Codexi
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE